Topo I/COX-2-IN-2

Topo I/COX-2-IN-2(Compound W10)是一种有效的 Topo I 和 COX-2 双靶点抑制剂,IC50 值分别为 0.90 μM 和 2.31 μM,并通过线粒体途径诱导癌细胞凋亡(apoptosis)。
产品编号: MS-Z77216 CAS No.: 2841455-91-0 分子式: C24H25ClN4O 分子量: 420.93
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Topo I/COX-2-IN-2(Compound W10)是一种有效的 Topo I 和 COX-2 双靶点抑制剂,IC50 值分别为 0.90 μM 和 2.31 μM,并通过线粒体途径诱导癌细胞凋亡(apoptosis)。

生物实验数据

生物活性 Topo I/COX-2-IN-2 (Compound W10) is a potent dual-target inhibitor of Topo I and COX-2 with IC50 values of 0.90 μM and 2.31 μM, respectively, and induces apoptosis in cancer cells via the mitochondrial pathway.
IC50 & Target

Topoisomerase I

0.90 μM (IC50)

COX-2

2.31 μM (IC50)

体外研究
(In Vitro)

Topo I/COX-2-IN-2 (Compound W10) (0-30 μM) shows good toxicity against cancer cells.
Topo I/COX-2-IN-2 forms an ionic bonding interaction with DA13 of DNA to improve Topo I inhibition.
Topo I/COX-2-IN-2 (0-9 μM, 24 h) arrests cell cycle of HT29 and RKO at G1/G0 phase, induces apoptosis in HT29 and RKO cells through the mitochondrial pathway, and inhibits abnormal activation of the NF-κB/IκB pathway..

Cell Proliferation Assay

Cell Line: HT29, RKO, HCT116, LoVo and SW480
Concentration: 0-30 μM
Incubation Time: 72 h
Result: Showed good toxicity with IC50 values of 1.48 ± 0.08 μM, 2.06 ± 0.01 μM, 4.89 ± 0.36 μM, 8.42 ± 0.22 μM and 7.36 ± 0.64 μM for HT29, RKO, HCT116, LoVo and SW480 cells, respectively.

Cell Cycle Analysis

Cell Line: HT29 and RKO
Concentration: 2, 4 and 8 μM for HT29; 3, 6 and 9 μM for RKO
Incubation Time: 24 h
Result: Blocked the cell cycle in G1/G0 phase in both HT29 and RKO. In HT29 cells, the arresting activity was not obvious for the ratio of G1/G0 phase in high-concentration treatment group increased from 55.20% to 65.17% slightly, while in RKO cells, the ratio of G1/G0 phase obviously increased from 37.57% to 76.99%.

Apoptosis Analysis

Cell Line: HT29 and RKO
Concentration: 2, 4 and 8 μM for HT29; 3, 6 and 9 μM for RKO
Incubation Time: 24 h
Result: Mainly induced the late apoptosis in HT29 cells and exhibited dual induction of late and early apoptosis in RKO cells.
Induced the production of reactive oxygen species (ROS) burst and significantly reduce the mitochondrial membrane potential.

Western Blot Analysis

Cell Line: HT29 and RKO
Concentration: 2, 4 and 8 μM for HT29; 3, 6 and 9 μM for RKO
Incubation Time: 24 h
Result: Induced increased expression of the pro-apoptotic proteins Bax, cytochrome c and apoptotic effector cleaved caspase 3/9, reduced the expression of the inhibitory factor Bcl-2.
The expressions of phosphorylated NF-κB and IκB were significantly decreased.
体内研究
(In Vivo)

Topo I/COX-2-IN-2 (Compound W10) (15 and 30 mg/kg; i.p.; b.i.d for 2 weeks) inhibits tumor growth and shows obvious necrosis on tumor tissue.
Topo I/COX-2-IN-2 has acceptable pharmacokinetic properties for intraperitoneal injection and oral administration.

Animal Model: Male BALB/c nude mice weighing 20–25 g, HT29 xenograft model
Dosage: 15 and 30 mg/kg
Administration: Intraperitoneal injection, twice daily for 2 weeks
Result: 30 mg/kg group immediately slowed down the tumor growth rate after administration, and almost completely prevented tumor growth in the later stage, and its tumor growth inhibition (TGI) was 57.86%. 15 mg/kg group showed 40.67% TGI.
Showed obvious necrosis on tumor tissue.
Animal Model: 250–280 g male SD rats
Dosage: 100 mg/kg and 30 mg/kg
Administration: Intragastric administration (100 mg/kg) or intraperitoneal injection (30 mg/kg) (Pharmacokinetics Study)
Result: Pharmacokinetic data of Topo I/COX-2-IN-2 (W10) in vivoa
Comp. Dose
(mg/kg)
Route T1/2(h) Tmax(h) Cmax
(μg/mL)
AUC0-t
(μg⋅h/mL)
Topo I/COX-2-IN-2 100 p.o. 8.87 ± 1.92 3.67 ± 0.58 2.00 ± 0.41 24.81 ± 5.76
30 i.p. 4.27 ± 0.22 0.28 ± 0.05 1.60 ± 0.34 5.41 ± 0.20

a Topo I/COX-2-IN-2 was administered to 6 SD rats with different administration methods and doses, and the serum concentration was analyzed. The analysis method is the linear trapezoidal PKsolver 2.0 computer program of the non-compartmental model. All the data are from the above 6 rats, and the data are represented by the mean and standard deviation.

化学信息

分子量 420.93
分子式 C24H25ClN4O
CAS No. 2841455-91-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础